Immunome, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Immunome, Inc. (IMNM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 1.55 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 1.05M shares, a 54.84% increase year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 500.00K shares, a 123.21% increase year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 176.00K shares, a 87.81% decline year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 4.48M shares, a 44.14% increase year-over-year.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 5.56M shares, a 15.92% decline from fiscal 2024.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 6.62M shares, a 65.09% increase from fiscal 2023.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 4.01M shares, a 610.68% increase from fiscal 2022.
- Immunome, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 563.90K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.05M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 1.55M shares 10-Q · filed 2026-08-11 | 1.73M shares derived: sum of 3 quarters · filed 2026-08-11 | 6.21M shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 500.00K shares 10-Q · filed 2026-05-12 | 676.00K shares derived: sum of 2 quarters · filed 2026-05-12 | 5.16M shares derived: sum of 3 quarters · filed 2026-05-12 | 5.84M shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 176.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 4.66M shares derived: sum of 2 quarters · filed 2026-03-03 | 5.34M shares derived: sum of 3 quarters · filed 2026-03-03 | 5.56M shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 4.48M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 5.16M shares derived: sum of 2 quarters · filed 2025-11-06 | 5.39M shares 10-Q · filed 2025-11-06 | 6.83M shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 678.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 902.68K shares 10-Q · filed 2025-08-06 | 2.35M shares derived: sum of 3 quarters · filed 2025-08-06 | 5.46M shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 224.00K shares 10-Q · filed 2025-05-12 | 1.67M shares derived: sum of 2 quarters · filed 2025-05-12 | 4.78M shares derived: sum of 3 quarters · filed 2025-05-12 | 5.71M shares derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-12-31 | 1.44M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | 4.55M shares derived: sum of 2 quarters · filed 2025-03-19 | 5.49M shares derived: sum of 3 quarters · filed 2025-03-19 | 6.62M shares 10-K · filed 2025-03-19 |
| 2024-09-30 | 3.11M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 4.04M shares derived: sum of 2 quarters · filed 2024-11-13 | 5.17M shares 10-Q · filed 2024-11-13 | 8.52M shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 932.13K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 2.06M shares 10-Q · filed 2024-08-12 | 5.41M shares derived: sum of 3 quarters · filed 2024-08-12 | 5.41M shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 1.13M shares 10-Q · filed 2024-05-14 | 4.48M shares derived: sum of 2 quarters · filed 2024-05-14 | 4.48M shares derived: sum of 3 quarters · filed 2024-05-14 | 5.11M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 3.35M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 3.35M shares derived: sum of 2 quarters · filed 2024-03-28 | 3.98M shares derived: sum of 3 quarters · filed 2024-03-28 | 4.01M shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 629.80K shares derived: sum of 2 quarters · filed 2023-11-09 | 658.90K shares 10-Q · filed 2023-11-09 | 678.90K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 629.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 658.90K shares 10-Q · filed 2023-08-09 | 678.90K shares derived: sum of 3 quarters · filed 2023-08-09 | |
| 2023-03-31 | 29.10K shares 10-Q · filed 2023-05-05 | 49.10K shares derived: sum of 2 quarters · filed 2023-05-05 | ||
| 2022-12-31 | 20.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 563.90K shares 10-K · filed 2023-03-16 | ||
| 2022-09-30 | 543.90K shares 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |